Skip to main content
. 2021 Mar 15;8(6):ofab127. doi: 10.1093/ofid/ofab127

Table 1.

Active TB Disease Status at Study Enrollment Among Adult Patients With Pulmonary TB Who Initiated Second-Line Anti-TB Treatment Within the Georgian National TB Program During 2011–2014 and Were Subsequently Defined as LFU (N = 92 Study Participants Who Were Tested)

Characteristics Total TB+ TB−
Na (%) = 92 (100) n (%) = 13 (14) n (%) = 79 (86) OR (95% CI) P Value
Demographics
Gender .69
 Male 82 (89.1) 12 (14.6) 70 (85.4) 1.5 (0.2–13.3)
 Female 10 (10.9) 1 (10.0) 9 (90.0) 1b
Age*
 Median (IQR) 42.5 (15.9) 40.5 (13) 43 (16.4) .62c
Age Categories .82
 0–40 38 (41.3) 5 (13.2) 33 (86.8) 1
 41+ 54 (58.7) 8 (14.8) 46 (85.2) 1.2 (0.3–3.8)
Region .38
 Tbilisi 26 (28.3) 5 (19.2) 21 (80.8) 1.7 (0.5–5.9)
 Other 66 (71.7) 8 (12.1) 58 (87.9) 1
Employment Status .48
 Employed 21 (23.1) 2 (9.5) 19 (90.5) 1
 Unemployed 70 (76.9) 11 (15.7) 59 (84.3) 1.8 (0.4–8.7)
Income*
 Median (IQR) 3600 (3600) 3600 (1800) 3840 (3600) .73c
Education .38
 High School or low 68 (74.7) 11 (16.2) 57 (83.8) 2.0 (0.4–9.9)
 Above High School 23 (25.3) 2 (8.7) 21 (91.3) 1
Marital Status .28
 Currently married 55 (61.1) 6 (10.9) 49 (89.1) 1
 Never married 21 (23.3) 6 (28.6) 15 (71.4) 3.3 (0.9–11.6)
 Widow 0 (0) 0 (0) 0 (0) -
 Divorced 12 (13.3) 1 (8.3) 11 (91.7) 0.7 (0.1–6.8)
 Missing/Refusal 2 (2.2) 2 (100) 0 (0) -
Number of household members (in addition to patient)
Median (IQR) 3 (2) 3 (4) 3 (2) .75c
Drug intake regularity during the latest episode of treatment .22
 Regular 75 (81.5) 9 (12) 66 (88) 1
 Irregular 17 (18.5) 4 (23.5) 13 (76.5) 2.3 (0.6–8.4)
Medicine Intake During the Latest Episode of Treatment .63
 All prescribed drugs 62 (67.4) 8 (12.9) 54 (87.1) 1
 Not all prescribed drugs 30 (32.6) 5 (16.7) 25 (83.3) 1.4 (0.4–4.6)
Treatment Adherence (Combined Variable) .33
 Full adherence 55 (59.8) 7 (12.7) 48 (87.3) 1
 Partial adherence 27 (29.3) 3 (11.1) 24 (88.9) 0.9 (0.2–3.6)
 No adherence 10 (10.9) 3 (30.0) 7 (70.0) 2.9 (0.6–14.1)
Culture Status Before LFU <.01
 Negative 74 (84.1) 3 (4.1) 71 (95.9) 1
 Positive 14 (15.9) 8 (57.1) 6 (42.9) 31.6 (6.6–151.2)
Re-Enter Treatment After Initial LFU .03
 Yes 38 (41.3) 9 (23.7) 29 (76.3) 3.9 (1.1–13.7)
 No 54 (58.7) 4 (7.4) 50 (92.6) 1
Days on Treatment During Last Episode*
 Median (IQR) 341 (290) 171 (391) 342 (258) .15c
Days From LFU to Study Enrollment*
 Median (IQR) 1095 (715) 480 (803) 1119 (627) <.01c
Current Signs and Symptoms
Cough .73
 Yes 18 (19.6) 3 (16.7) 15 (83.3) 1.3 (0.3–5.2)
 No 74 (80.4) 10 (13.5) 64 (86.5) 1
Cough With Blood or Vomiting Blood During the Last 3 Months
 Yes 2 (2.2) 0 (0) 2 (100)
 No 90 (97.8) 13 (14.4) 77 (85.6)
Fever .99
 Yes 7 (7.6) 1 (14.3) 6 (85.7) 1.0
 No 85 (92.4) 12 (14.1) 73 (85.9) 1
Significant Weight Loss (≥3 kg in 1 Month) .68
 Yes 10 (11) 1 (10) 9 (90) 0.6 (0.1–5.5)
 No 81 (89) 12 (14.8) 69 (85.2) 1
Night Sweats .91
 Yes 15 (16.5) 2 (13.3) 13 (86.7) 0.9 (0.2–4.6)
 No 76 (83.5) 11 (14.5) 65 (85.5) 1
Chest Pain .83
 Yes 19 (20.9) 3 (15.8) 16 (84.2) 1.2 (0.3–4.7)
 No 72 (79.1) 10 (13.9) 62 (86.1) 1

Abbreviations: CI, confidence interval; IQR, interquartile range; LFU, loss to follow-up; OR, odds ratio; TB, tuberculosis.

NOTE: Continuous variables (*) are presented as median (IQR), and categorical variables are summarized as frequencies (valid percentage).

aIndividual variable totals might not sum up to 92 due to missing values.

b1 = reference value.

c P value from Wilcoxon signed-rank test.